Peptide & Compound Guide
At a glance
| Compound | Retatrutide |
|---|---|
| Type | Investigational GIP/GLP-1/glucagon receptor agonist |
| U.S. regulatory context | Investigational; not FDA approved as of this guide |
| Evidence level | Human clinical trials; clinical development ongoing |
| Research area | Obesity, metabolic health and cardiometabolic outcomes |
What is Retatrutide?
Retatrutide is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. It has generated substantial interest because early and mid-stage clinical studies reported meaningful effects on body weight and metabolic measures.
What does the research examine?
The important question is not whether early results are promising, but whether larger and longer trials confirm benefits, characterize risks and support regulatory approval. Clinical development should be followed through trial registries and peer-reviewed publications.
What has not been established?
Mechanism, biomarker changes, animal findings and early clinical signals are not the same as proof that a compound safely improves meaningful health outcomes. Claims should be matched to the type, size and quality of evidence available.
Safety and regulatory context
Retatrutide is not an FDA-approved medication. Products marketed outside legitimate clinical research should not be assumed equivalent to material used in clinical trials.
Related: Retatrutide vs. Tirzepatide
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.